Reports FY24 revenue $32M vs $31.3M last year. David Portnoy, Cryo-Cell’s (CCEL) Chairman of the Board and Co-CEO remarked, “The Company’s 2024 fiscal results were impacted by continued investments related to the Duke License Agreement. We expect reduced expenditures related thereto this year; however, higher legal expenses are anticipated in fiscal year 2025 versus fiscal year 2024.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue